| Regulatory Rapporteur November 2021 | MEMBERS |
| EUAs – How they came into their own with COVID-19 | MEMBERS |
| France implements major changes in its early access framework | MEMBERS |
| C-Path collaborations to accelerate medicines development for rare diseases | MEMBERS |
| Navigating the regulatory challenges of plasmids and synthetic DNA as starting material for mRNA vaccines | MEMBERS |
| Strategic regulatory considerations for tablet imprinting | MEMBERS |
| Lessons from the pandemic are shaping the future | MEMBERS |
| Stakeholders input into EU standards for data sharing | MEMBERS |
| Ad/promo submissions and the eCTD mandate | MEMBERS |
| Regulation of medicines in Denmark | MEMBERS |